Pfenex recombinant anthrax vaccine receives active IND status

The recombinant anthrax vaccine Px563L received active Investigational New Drug (IND) status and additional funding through the Biomedical Advanced Research and Development Authority (BARDA) from the Department of Health and Human Services, developer Pfenex Inc. said Monday.

"We are extremely pleased to have the IND now active for our recombinant anthrax vaccine, Px563L. This represents a significant milestone in our company's partnership with BARDA as we continue to advance this important program," Pfenex CEO Bertrand C. Liang said. "We appreciate the additional funding support provided by BARDA for this program and look forward to continuing this successful collaboration."

Pfenex develops high-value, difficult to manufacture proteins and biosimilar therapeutics. Pfenex's PF582, for the treatment of retinal diseases, is the company's leading product candidate. Through the Pfenex Expression Technology platform, the company has begun development of other products such as vaccines, next generation biologics, generics and other biosimilars.

Organizations in this Story


Want to get notified whenever we write about Pfenex ?
Next time we write about Pfenex, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.